FY2024 Earnings Forecast for Moderna Issued By William Blair

Moderna, Inc. (NASDAQ:MRNA) – Research analysts at William Blair raised their FY2024 EPS estimates for Moderna in a report issued on Tuesday, January 14th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($8.77) per share for the year, up from their previous estimate of ($9.04). The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. William Blair also issued estimates for Moderna’s Q4 2024 earnings at ($2.33) EPS, Q1 2025 earnings at ($2.86) EPS, Q2 2025 earnings at ($2.59) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($6.76) EPS.

Several other research analysts also recently commented on the stock. Leerink Partners decreased their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday. Argus lowered shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Morgan Stanley reduced their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a report on Monday, November 18th. Finally, Jefferies Financial Group reduced their target price on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Four analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $75.58.

Moderna Price Performance

Shares of Moderna stock opened at $34.06 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. Moderna has a one year low of $31.94 and a one year high of $170.47. The business’s 50 day simple moving average is $40.85 and its two-hundred day simple moving average is $66.75. The stock has a market capitalization of $13.11 billion, a P/E ratio of -5.85 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.39) EPS.

Institutional Investors Weigh In On Moderna

Hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its position in Moderna by 108.0% in the 4th quarter. SG Americas Securities LLC now owns 109,761 shares of the company’s stock valued at $4,564,000 after acquiring an additional 56,982 shares during the last quarter. Mirabaud & Cie SA boosted its position in Moderna by 3.0% in the 4th quarter. Mirabaud & Cie SA now owns 58,022 shares of the company’s stock valued at $2,413,000 after buying an additional 1,694 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after acquiring an additional 389 shares during the period. Arkadios Wealth Advisors increased its position in shares of Moderna by 7.3% during the fourth quarter. Arkadios Wealth Advisors now owns 12,265 shares of the company’s stock worth $510,000 after acquiring an additional 836 shares during the period. Finally, Avanza Fonder AB bought a new stake in shares of Moderna during the fourth quarter valued at approximately $1,393,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is currently owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.